These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 10722742)

  • 1. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
    J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.
    Honda R; Yasuda H
    Oncogene; 2000 Mar; 19(11):1473-6. PubMed ID: 10723139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    Honda R; Tanaka H; Yasuda H
    FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.
    Rajendra R; Malegaonkar D; Pungaliya P; Marshall H; Rasheed Z; Brownell J; Liu LF; Lutzker S; Saleem A; Rubin EH
    J Biol Chem; 2004 Aug; 279(35):36440-4. PubMed ID: 15247280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p53-Mdm2 module and the ubiquitin system.
    Michael D; Oren M
    Semin Cancer Biol; 2003 Feb; 13(1):49-58. PubMed ID: 12507556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical contribution of the MDM2 acidic domain to p53 ubiquitination.
    Kawai H; Wiederschain D; Yuan ZM
    Mol Cell Biol; 2003 Jul; 23(14):4939-47. PubMed ID: 12832479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
    Ranaweera RS; Yang X
    J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2.
    Singh RK; Iyappan S; Scheffner M
    J Biol Chem; 2007 Apr; 282(15):10901-7. PubMed ID: 17301054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of the RING finger domain of MDM2 to cell cycle progression.
    Argentini M; Barboule N; Wasylyk B
    Oncogene; 2000 Aug; 19(34):3849-57. PubMed ID: 10951578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.
    Buschmann T; Fuchs SY; Lee CG; Pan ZQ; Ronai Z
    Cell; 2000 Jun; 101(7):753-62. PubMed ID: 10892746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of p53 by Mdm2: fate is in the numbers.
    Shmueli A; Oren M
    Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.
    Zhang Z; Wang H; Li M; Agrawal S; Chen X; Zhang R
    J Biol Chem; 2004 Apr; 279(16):16000-6. PubMed ID: 14761977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.